Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Conference Coverage

Conference Coverage
Apatinib Safe, Effective for the Treatment of Advanced Platinum-Resistant Recurrent Epithelial Ovarian Cancer
06/08/2022

Marta Rybczynski

Marta Rybczynski
Apatinib therapy may be effective among patients with advanced platinum-resistant relapsed epithelial ovarian cancer, with manageable toxicities, according to a study presented at ASCO 2022.
Apatinib therapy may be effective among patients with advanced platinum-resistant relapsed epithelial ovarian cancer, with manageable toxicities, according to a study presented at ASCO 2022.
Apatinib therapy may be...
06/08/2022
Journal of Clinical Pathways
Conference Coverage
Understanding Oncologists’ Attitudes on Communicating With Patients About the Cost of Cancer
06/08/2022

Amber Denham

Amber Denham
According to data from an online survey summarized at the 2022 ASCO Annual Meeting, despite believing cost of cancer care should be discussed in the clinic, most hematologists/oncologists surveyed did not do so.
According to data from an online survey summarized at the 2022 ASCO Annual Meeting, despite believing cost of cancer care should be discussed in the clinic, most hematologists/oncologists surveyed did not do so.
According to data from an online...
06/08/2022
Journal of Clinical Pathways

Advertisement

Conference Coverage
Real-world Treatment Patterns for Patients With Metastatic Castration-Resistant Prostate Cancer
06/06/2022

Robert Fee

Robert Fee
Although numerous treatments with different mechanisms of action are approved for metastatic castration-resistant prostate cancer (mCRPC), the sequencing for management of these patients has been evolving post availability of trials.
Although numerous treatments with different mechanisms of action are approved for metastatic castration-resistant prostate cancer (mCRPC), the sequencing for management of these patients has been evolving post availability of trials.
Although numerous treatments...
06/06/2022
Journal of Clinical Pathways
Conference Coverage
The Financial Impact of Biosimilar Adoption in the Oncology Care Model
06/05/2022

Robert Fee

Robert Fee
In a study presented at the 2022 ASCO Annual Meeting, researchers examined the utilization and the financial impact of biosimilar adoption in The US Oncology Network Over a six-month period.
In a study presented at the 2022 ASCO Annual Meeting, researchers examined the utilization and the financial impact of biosimilar adoption in The US Oncology Network Over a six-month period.
In a study presented at the 2022...
06/05/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Survival Outcomes With PARP Inhibitor Maintenance in Advanced Ovarian Cancer
06/05/2022

Robert Fee

Robert Fee
Study examines patient records over five years to determine real-world efficacy benefits of PARPi therapy vs active surveillance confirms the efficacy benefits that have been demonstrated in randomized clinical trials of PARPis vs placebo.
Study examines patient records over five years to determine real-world efficacy benefits of PARPi therapy vs active surveillance confirms the efficacy benefits that have been demonstrated in randomized clinical trials of PARPis vs placebo.
Study examines patient records...
06/05/2022
Journal of Clinical Pathways

Advertisement

Conference Coverage
Bevacizumab-awwb Safe, Effective Among Patients With Metastatic Colorectal Cancer
06/04/2022

Robert Fee

Robert Fee
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world effectiveness and safety of Bevacizumab-awwb, the first FDA-approved biosimilar to Avastin, among patients with metastatic colorectal cancer.
Study examines real-world...
06/04/2022
Journal of Clinical Pathways
Conference Coverage
Clinical Implications of Tumor-Based Next-generation Sequencing in Ovarian Cancer
06/04/2022

Robert Fee

Robert Fee
A study presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting assessed the clinical relevance of tumor-based next-generation sequencing (tbNGS) in a large cohort of patients with high-grade epithelial ovarian...
A study presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting assessed the clinical relevance of tumor-based next-generation sequencing (tbNGS) in a large cohort of patients with high-grade epithelial ovarian...
A study presented at the 2022...
06/04/2022
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization and Comparative Effectiveness of Treatment Options for Cancer–Associated Venous Thromboembolism
06/04/2022

Janelle Bradley

Janelle Bradley
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting, patients with cancer–associated venous thromboembolism remain on anticoagulation for a short period of time and DOACs and warfarin may be associated with better compliance than low molecular weight heparin.
In the real-world setting,...
06/04/2022
Journal of Clinical Pathways

Advertisement

Conference Coverage
Pharmacist Interventions in Oral Oncolytics Program Shown to Provide Cost Savings
06/04/2022

Robert Fee

Robert Fee
A study presented at the 2022 ASCO Annual Meeting shows that pharmacist interventions in the Pharmacist-Managed Oral Chemotherapy Clinic at Kaiser Permanente San Diego led to significant overall cost savings to the health care system.
A study presented at the 2022 ASCO Annual Meeting shows that pharmacist interventions in the Pharmacist-Managed Oral Chemotherapy Clinic at Kaiser Permanente San Diego led to significant overall cost savings to the health care system.
A study presented at the 2022...
06/04/2022
Journal of Clinical Pathways
Conference Coverage
Bendamustine Plus Rituximab Among Older Patients With Newly Diagnosed Mantle Cell Lymphoma
06/04/2022

Robert Fee

Robert Fee
Research presented at ASCO demonstrates that ibrutinib, when combined with bendamustine-rituximab, improved progression-free survival by 50% for older patients with newly diagnosed mantle cell lymphoma.
Research presented at ASCO demonstrates that ibrutinib, when combined with bendamustine-rituximab, improved progression-free survival by 50% for older patients with newly diagnosed mantle cell lymphoma.
Research presented at ASCO...
06/04/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use